Results 41 to 50 of about 819 (177)
In Vitro Dissolution and in Silico Modeling Shortcuts in Bioequivalence Testing
Purpose: To review in vitro testing and simulation platforms that are in current use to predict in vivo performances of generic products as well as other situations to provide evidence for biowaiver and support drug formulations development.
Moawia M. Al-Tabakha, Muaed J. Alomar
doaj +1 more source
A dual‐layer high‐pressure drug‐coated balloon (HP@DCB) increased balloon‐wall contact and promoted deeper paclitaxel (PTX) penetration than a conventional noncompliant DCB. In in vivo study, HP@DCB treatment improved luminal patency and reduced neointimal hyperplasia, supporting pressure‐assisted drug delivery as a promising strategy for enhancing the
Seung Jin Eo +10 more
wiley +1 more source
Anti‐PD‐1/PD‐L1 blockade has revolutionized cancer immunotherapy, but is ineffective against endocrine‐treated (i.e., Tamoxifen), relapsed ER+ breast cancer (BC) patients. This study provides insight into the sub‐optimal response of ER+BCs to anti‐PD‐1/PD‐L1 blockade – highlighting the induction of STING and the CEACAM1/TIM3 axis after chronic ...
Marvin Angelo E Aberin +20 more
wiley +1 more source
Lactiplantibacillus plantarum GUANKE remodels the indigenous gut microbiota and is associated with microbiota‐dependent restoration of circulating IAA. IAA treatment attenuates JAK3‐STAT3 and Jag1‐Notch4‐Hey1 signaling and reduces CX3CR1+Ly6C− monocytic precursor generation and pulmonary CD11b+ DC accumulation, together with reduced Th2 inflammation ...
Yujia He +10 more
wiley +1 more source
Self‐Assembling Peptide‐Adjuvant Conjugate (SaPAC) Platform for Precision Cancer Immunotherapy
A self‐assembling peptide–adjuvant conjugate links neoantigens to TLR7 agonism, forming cationic nanoparticles that enhance lymph‐node retention, dendritic‐cell activation, and antitumor T‐cell immunity. This chemically defined platform shows how synchronized antigen and innate stimulation can be adapted across melanoma, bladder cancer, and triple ...
Yang‐Fan Wu +15 more
wiley +1 more source
TROP2 is identified as a novel tumor‐selective lysosomal‐targeting receptor with established clinical relevance. TROP2‐targeting chimeras (TRTACs) are developed by genetically fusing a TROP2‐binding nanobody to nanobodies against specific target proteins.
Luping Chen +10 more
wiley +1 more source
Biopharmaceutical classification system (BCS) class IV drugs (low-solubility low-permeability) are generally poor drug candidates, yet, ~5% of oral drugs on the market belong to this class.
Milica Markovic +4 more
doaj +1 more source
Abstract Objectives The aim of this study was (1) to determine how closely physiologically based pharmacokinetic (PBPK) models can predict oral bioavailability using a priori knowledge of drug-specific properties and (2) to examine the influence of the biopharmaceutics classification system ...
Hansmann +5 more
openaire +4 more sources
This Review outlines the biological framework of entry, maintenance, and awakening in dormant minimal residual disease across gynecologic cancers. By mapping critical biological dependencies—from metabolic plasticity to microenvironment interactions—it evaluates novel interception concepts and presents a translational framework combining single‐cell ...
Shih‐Hsuan Cheng +7 more
wiley +1 more source
Huntingtin Aggregate‐Responsive Autophagy Gene Circuit Mitigates Disease Pathology in R6/2 Mice
CD98‐mediated receptor‐mediated transcytosis enables LIP‐CD98 nanocarriers to cross the blood–brain barrier and deliver ARAA to neurons. mHTT aggregates activate the 11G–NarX sensor, initiating Auto‐P and Trans‐P signaling through the VP48–NarL relay.
Jie Zhu +8 more
wiley +1 more source

